Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.
E John TokarskyJesse C CrowLillian M GuentherJohn ShermanCenny TaslimGabriela AlexeKathleen I PishasGalen RaskBlake S JustisAna KasumovaKimberly StegmaierStephen L LessnickEmily Rose TheisenPublished in: Molecular cancer research : MCR (2022)
These findings demonstrate that mitochondrial dysfunction modulates SP-2509 efficacy and suggest that new therapeutic strategies combining LSD1 with agents that prevent mitochondrial dysfunction may benefit patients with this aggressive malignancy.
Keyphrases